As SVP of DMPK and Clinical Pharmacology, Dr. Jin Chen provides leadership in the development and advancement of HighTide’s pipeline. Dr. Chen has over 17 years of industry experience in clinical pharmacology and clinical development, and contributed to the development of therapeutics for numerous therapeutic areas, including cardiovascular and metabolic diseases as well as liver diseases.
Prior to HighTide, Dr. Chen served various roles at Novartis from 2006 to 2021, including Clinical Development Director and Clinical Pharmacology Director, where she contributed to multiple IND submissions, an NDA submission and global approval of Exforge HCT® for the treatment of hypertension. She also contributed to the global submission preparation of Pradigastat. In addition, Dr. Chen participated in due-diligence and licensing activities for over 20 programs. Prior to Novartis, Dr. Chen served as Clinical PK Scientist at Amgen.
Dr. Chen holds a Ph.D. in Pharmaceutical Sciences from the University at Buffalo, the State University of New York.